- Gilbert Group
The main focus of my research is to generate Simian adenoviral vectored vaccines for a range of emerging and re-emerging pathogens including SARS CoV-2. Emerging pathogen outbreaks require a quick and efficient response. Manufacturing methods for Adenovirus vectors at large scale have been developed, however the process from selecting an antigen to starting a clinical trial takes at least 18 months, which has ruled out the current manufacturing technology in the event of a pandemic. I have been working on improving the manufacturing processes for Adenovirus vaccines to minimise the time required from concept to end product. I work closely with the Clinical Biomanufacturing facility to ensure all processes are transferable to a GMP environment.
Another aspect of my research is the design and development of new viral vectors.
Simian adenoviruses as vaccine vectors
Morris SJ. et al, (2016), Future Virology, 11, 649 - 659
Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter
Alharbi NK. et al, (2016), Vaccine, 34, 49 - 55
Laboratory-Scale Production of Replication-Deficient Adenovirus Vectored Vaccines
Morris SJ. et al, (2016), Methods in Molecular Biology, 121 - 135
The Human Adenovirus Type 5 L4 Promoter Is Negatively Regulated by TFII-I and L4-33K
Wright J. et al, (2015), Journal of Virology, 89, 7053 - 7063
Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors
Cottingham MG. et al, (2012), Biotechnology and Bioengineering, 109, 719 - 728